Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR 4.595
-0.180 (-3.77%)
Apr 21, 2026, 5:35 PM CET
Inventiva Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
It also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Inventiva S.A.
| Country | France |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 77 |
| CEO | Andrew Obenshain |
Contact Details
Address: 50 rue de Dijon Daix, 21121 France | |
| Phone | 33 3 80 44 75 00 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | IVA |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013233012 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nazira Amra M.D. | Chief Commercial Strategy Officer |